Patents by Inventor Xinbin Gu

Xinbin Gu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammal-specific Growth-defective Arbovirus
    Publication number: 20210222132
    Abstract: Arbovirus carries an altered furin cleavage site that results in enhanced cleavage of a precursor polyprotein, such as, prE2 or prM. Dengue virus particles can have an amino acid alteration within amino acids 80-130 of prM. Zika virus particles can have alterations at amino residues at and/or about the furin cleavage site. The virus can be produced in insect cells. The virus does not form progeny virus in mammal cells.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 22, 2021
    Inventors: Xiaowu Pang, Xinbin Gu
  • METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID B
    Publication number: 20210106552
    Abstract: The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the ceramide-mediated apoptosis of TNBC cells occurs by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of salvianolic acid B. In another aspect, salvianolic acid B or its pharmaceutically acceptable salt or solvate is used as a medicament or in the manufacture of a medicament for treating TNBC.
    Type: Application
    Filed: April 11, 2019
    Publication date: April 15, 2021
    Applicant: Howard University
    Inventor: Xinbin GU
  • Salivary biomarkers for monitoring of type 2 diabetes treatment
    Patent number: 10317415
    Abstract: The disclosure relates to the identification of salivary biomarkers for diagnosis and monitoring of type 2 diabetes in a subject. Also provided are methods for noninvasively diagnosing and monitoring type 2 diabetes in a subject. More particularly, the expression of salivary biomarkers, including MUC-1, MUC-2, MUC-4, and MUC-5B, are highly associated with A1C level in African American patients with type 2 diabetes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 11, 2019
    Assignee: Howard University
    Inventors: Xinbin Gu, Grace Robinson
  • Flavivirus Vaccine
    Publication number: 20180340011
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Application
    Filed: August 6, 2018
    Publication date: November 29, 2018
    Inventors: Xiaowu Pang, Xinbin Gu
  • Flavivirus vaccine
    Patent number: 10040824
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2018
    Assignee: Tengen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu
  • Salivary Biomarkers For Diagnosis And Monitoring Of Type 2 Diabetes And Uses Thereof
    Publication number: 20160266148
    Abstract: The disclosure relates to the identification of salivary biomarkers for diagnosis and monitoring of type 2 diabetes in a subject. Also provided are methods for noninvasively diagnosing and monitoring type 2 diabetes in a subject. More particularly, the expression of salivary biomarkers, including MUC-1, MUC-2, MUC-4, and MUC-5B, are highly associated with A1C level in African American patients with type 2 diabetes.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Applicant: Howard University
    Inventors: Xinbin Gu, Grace Robinson
  • FLAVIVIRUS VACCINE
    Publication number: 20070249032
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Application
    Filed: January 11, 2007
    Publication date: October 25, 2007
    Applicant: TenGen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu